February 11, 2003
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, DC 20549
Re: Schedule 13G - Transgenomic, Inc.
Gentlemen:
Pursuant to Rule 13d-1 under the Securities and Exchange Act of 1934,
as amended (the "Exchange Act") and Rule 13d-2 of the General Rules and
Regulations promulgated pursuant to the Exchange Act, enclosed for filing
electronically is Schedule 13G Amendment No. 1 filed by GlaxoSmithKline plc with
respect to ownership of securities of Transgenomic, Inc.
Any questions concerning this filing may be directed to Donald F.
Parman at 215-751-7633.
Very truly yours,
/s/
S.M. Bicknell
Company Secretary
GlaxoSmithKline plc
cc w/encs: Transgenomic, Inc.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
TRANSGENOMIC, INC.
-------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 Par Value
-------------------------------------------------------------
(Title of Class of Securities)
89365K206
-------------------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ]. (A fee
is not required only if the filing person: (1) has a previous statement on the
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has no amendment subsequent thereto
reporting beneficial ownership of five percent or less of such class.) (See Rule
13d-7.)
*The remainder of this cover page shall be filled our for a reporting person's
initial filing of this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
The undersigned hereby amends and supplements Item 5 of the Initial Statement.
(Continued on following page(s))
CUSIP NO. 89365K206 13G
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GlaxoSmithKline plc
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
5 SOLE VOTING POWER
NUMBER OF 1,247,687
SHARES
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY
EACH
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 1,247,687
WITH
8 SHARED DISPOSITIVE POWER
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,247,687
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.3%
12 TYPE OF REPORTING PERSON*
CO
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP NO. 89365K206 13G
Item 1. (a). Name of Issuer:
(b). Address of Issuer's Principal Executive Offices:
Item 2. (a). Names of Person Filing:
(b). Address of Principal Business Office:
(c). Citizenship:
(d). Title of Class of Securities:
(e). CUSIP Number:
Item 3. Not Applicable.
Item 4. Ownership.
The information in items 1 and 5 through 11
on the cover pages (page 2) on Schedule 13G
Amendment No. 1 is hereby incorporated by
reference.
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that
as of the date hereof the reporting person has ceased to
be the beneficial owner of more than five percent of the
class of securities, check the following [ ].
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person:
All shares held in the escrow account described in the
Initial Statement were delivered to owners of record in
May 2002.
Item 7. Identification and Classification of Subsidiaries Which
Acquired the Security Being Reported on by the Parent
Holding Company:
Item 8. Identification and Classification of Members of the
Group:
Item 9. Notice of Dissolution of Group:
Item 10. Certification:
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above
were acquired and are not held for the purpose of or
with the effect of changing or influencing the control
of the issuer of such securities and were not acquired
in connection with or as a participant in any
transaction having such purpose or effect.
Signature:
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in
this statement is true, complete and correct.
GLAXOSMITHKLINE PLC
By: /s/_________________________
S.M. Bicknell
Company Secretary
Dated: February 11, 2003